Skip to content
SRPT·Nasdaq·US

Sarepta

Sarepta is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy and is developing therapeutic candidates for a broad range of diseases and disorders, including Duchenne and LGMD, often through collaborations with strategic partners such as Arrowhead Pharmaceuticals.

Source: SEC 10-K Mar 2, 2026

Thematic Position

SRPT

Relationship Groups

Suppliers2
Partners3
Licensing2
Competitors20

Relationship details are part of the Pro plan.

Ended Relationships

12 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

drug safety holdregulatory actionlabeling restriction
FDA requests voluntary halt of ELEVIDYS shipments over ALF safety signals
SEC 10-KMar 2, 2026

The full regulatory passage is part of the Pro plan.

26 more · Regulatory and geopolitical insights are part of the Pro plan.